[go: up one dir, main page]

NO994903L - Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators - Google Patents

Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators

Info

Publication number
NO994903L
NO994903L NO994903A NO994903A NO994903L NO 994903 L NO994903 L NO 994903L NO 994903 A NO994903 A NO 994903A NO 994903 A NO994903 A NO 994903A NO 994903 L NO994903 L NO 994903L
Authority
NO
Norway
Prior art keywords
prophylaxis
estrogen receptor
selective estrogen
treatment
prostate cancer
Prior art date
Application number
NO994903A
Other languages
Norwegian (no)
Other versions
NO994903D0 (en
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994903D0 publication Critical patent/NO994903D0/en
Publication of NO994903L publication Critical patent/NO994903L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling eller profylakse av benign prostatahyperplasi eller prostatakreft hos en pasient som trenger slik behandling som innbefatter administrering av en selektiv østrogenreseptor- moduleringsforbindelse med formel (I), hvori R' og R^ uavhengig er hydroksy og alkoksy med 1 til 4 karbonatomer; og R' og R" er uavhengig metyl eller etyl, eller R' og R'', sammen med nitrogenatomet som de er bundet til danner en pyrrolidino, metyl- pyrrolidino, dimetylpyrrolidino, piperidino, morfolino eller heksametylenimino ring.The present invention provides a method for treating or prophylaxis of benign prostate hyperplasia or prostate cancer in a patient in need of treatment including administration of a selective estrogen receptor modulation compound of formula (I) wherein R 1 and R 2 are independently hydroxy and alkoxy of 1 to 4 carbon atoms; and R 'and R' are independently methyl or ethyl, or R 'and R' ', together with the nitrogen atom to which they are attached form a pyrrolidino, methylpyrrolidino, dimethylpyrrolidino, piperidino, morpholino or hexamethyleneimino ring.

NO994903A 1997-04-09 1999-10-08 Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators NO994903L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09
PCT/US1998/007274 WO1998045288A1 (en) 1997-04-09 1998-04-07 Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators

Publications (2)

Publication Number Publication Date
NO994903D0 NO994903D0 (en) 1999-10-08
NO994903L true NO994903L (en) 1999-12-09

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994903A NO994903L (en) 1997-04-09 1999-10-08 Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators

Country Status (16)

Country Link
EP (1) EP0975629A4 (en)
JP (1) JP2001518900A (en)
KR (1) KR20010006218A (en)
CN (1) CN1259944A (en)
AU (1) AU6966198A (en)
BR (1) BR9808515A (en)
CA (1) CA2286204A1 (en)
EA (1) EA199900914A1 (en)
HU (1) HUP0003589A3 (en)
ID (1) ID24358A (en)
IL (1) IL132277A0 (en)
NO (1) NO994903L (en)
PL (1) PL336205A1 (en)
TR (1) TR199902701T2 (en)
WO (1) WO1998045288A1 (en)
ZA (1) ZA982819B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
RU2261716C1 (en) * 2004-02-24 2005-10-10 Долженков Сергей Дмитриевич Method for prophylaxis of suppurative-inflammatory complications in patients with benign prostate hyperplasia in post-operative period
JP5123935B2 (en) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド Method for treating chronic non-bacterial prostatitis using selective estrogen receptor modulators or aromatase inhibitors
JP5558358B2 (en) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド TRANS-clomiphene for metabolic syndrome
JP2015508825A (en) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド Combination therapy to treat androgen deficiency
CA2899030C (en) 2013-02-19 2021-03-09 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
SG64896A1 (en) * 1995-02-28 1999-05-25 Lilly Co Eli Benzothiophene compounds intermediates compositions and methods
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
EP0975629A4 (en) 2001-03-21
CN1259944A (en) 2000-07-12
WO1998045288A1 (en) 1998-10-15
ZA982819B (en) 1999-10-04
BR9808515A (en) 2001-06-19
HUP0003589A3 (en) 2002-02-28
JP2001518900A (en) 2001-10-16
EP0975629A1 (en) 2000-02-02
HUP0003589A2 (en) 2002-01-28
IL132277A0 (en) 2001-03-19
EA199900914A1 (en) 2000-04-24
PL336205A1 (en) 2000-06-05
NO994903D0 (en) 1999-10-08
AU6966198A (en) 1998-10-30
CA2286204A1 (en) 1998-10-15
ID24358A (en) 2000-07-13
TR199902701T2 (en) 2000-02-21
KR20010006218A (en) 2001-01-26

Similar Documents

Publication Publication Date Title
NO994901L (en) Treatment of central nervous disorders by selective estrogen receptor modulators
MY125942A (en) Aminoalkoxy carbazoles for the treatment of cns diseases
DE69922216D1 (en) PORPHYRINE DERIVATIVES, THEIR USE IN PHOTODYNAMIC THERAPY AND THE MEDICAL DEVICES CONTAINING THEM
KR950701317A (en) Indole Derivative
BR9807674A (en) Bicyclic farnesyl transferase protein inhibitors
DE69329240D1 (en) 17-ETHER AND THIOETHER OF 4-AZA STEROIDS
NZ514663A (en) Indigoid bisindole derivatives for treating solid cancers
NO994903L (en) Treatment or prophylaxis of prostate cancer and benign prostate hyperplasia with selective estrogen receptor modulators
AU565185B2 (en) N-phenylbenzamide derivatives
AU6350699A (en) Chemical compounds
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
ATE156839T1 (en) NEW DELTA-17 AND DELTA-20 UNSATURATED AND SATURATED 17--G(B)-SUBSTITUTED-4-AZA-5-G(A)- ANDROSTAN-3-ONE COMPOUNDS AS INHIBITORS OF 5-ALPHA-REDUCTASE
UA72948C2 (en) Substituted derivatives of phenylpiperazine, a pharmaceutical composition and a method for treatment of affective or neurologic diseases and disorders
BR0011865A (en) aromatic and heterocyclic derivatives of phytoterols and / or phytostanols for use in the treatment and prevention of cardiovascular disease
DE69713273D1 (en) Use of 3,4-diphenylchromanes for the manufacture of a medicament for the treatment or prevention of prostate cancer
GB9727521D0 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
NO994902L (en) Breast cancer prevention by selective estrogen receptor modulators
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
ATE22294T1 (en) PYRIDO(3,4-C)PSORALENE, MANUFACTURE, USE IN COSMETOLOGY AND MEDICATIONS AND PREPARATIONS CONTAINING THESE.
YU46302A (en) Substituted pyrroles
NZ502537A (en) Androst-1-en-3-one derivatives and pharmaceutical formulations thereof; useful for the treatment of alopecia, female hirsutism, seborrhea, and useful for the prevention of bone metastasis caused by prostatic cancer
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
IL133392A0 (en) Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase
TR200003580T2 (en) Benzo (5,6) cyclohepta (1,2-B) pyridine derivatives for the prevention of farnesyl protein transferase
DE69528984D1 (en) INHIBITION OF LEUKOTRIA BIOSYNTHESIS BY URINE DERIVATIVES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application